| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD). Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients. |
| Category: | Health & biotech |
| URL: | http://www.opthea.com/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | OPT |
| Year of Commencement: | 2012 |
| Address: | Level 1, 10 Wallace Avenue, Toorak, Melbourne, VIC 3142, AU |
| State: | Victoria |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/opthea/ |
| Founders: | |
| Awards won: | |
